Eczema Beyond The Barrier: The Neuroimmune And Neurovascular Drivers Of Atopic Dermatitis

Eczema is usually explained as a broken skin barrier, but that misses why it itches so relentlessly and why the skin runs cold and reactive.

In this post, we will discuss the three real drivers of atopic dermatitis, the breakthrough that immune cytokines talk directly to itch nerves, why eczema skin is neurovascularly abnormal, and what actually calms it.

Eczema Is Three Problems, Not One

Atopic dermatitis is usually told as a single story: the skin barrier is broken, so irritants and allergens get in and cause inflammation.

That is true, but it is one third of the picture.

Eczema is actually three overlapping problems: a barrier defect, a Th2-skewed immune system, and a neuro-immune-vascular abnormality where the nerves and blood vessels behave abnormally. R

The barrier story explains the dryness and the irritant sensitivity.

The immune story explains the inflammation and the allergy.

But neither explains the defining feature of eczema, the maddening itch, or the strange way eczema skin reacts to touch and temperature.

For those, you need the nerves.

The Barrier Defect Is Real But Not The Whole Story

The barrier defect is genuine and important.

Loss-of-function variants in filaggrin (the FLG gene), the key barrier protein, are the strongest genetic risk factor for atopic dermatitis and cause a leaky, dry barrier that lets allergens and irritants reach the immune and nerve cells below. R

This is the "outside-in" model: a broken barrier drives the disease.

But many people with eczema have completely normal filaggrin, and many people with filaggrin mutations never get eczema.

So the barrier is a major contributor, not the sole cause.

There is also an "inside-out" model, where Th2 inflammation damages the barrier from within by suppressing the genes that build it.

Both are true at once, which is why barrier repair alone helps but rarely controls moderate to severe disease.

The Th2 Immune Skew

The immune signature of eczema is a Th2 (allergic) skew.

Atopic dermatitis skin is dominated by the Th2 cytokines interleukin-4 (IL-4), interleukin-13 (IL-13), and the itch cytokine interleukin-31 (IL-31). R

These cytokines drive the allergic inflammation, suppress the barrier proteins, and impair the antimicrobial defense that normally keeps Staph aureus in check.

The success of dupilumab, an antibody that blocks IL-4 and IL-13 signaling, confirmed how central this Th2 axis is.

But the discovery of exactly how IL-4 and IL-13 cause itch is what rewired the whole field.

The Breakthrough: Cytokines Talk Directly To Nerves

For a long time, the assumption was that immune cytokines caused itch indirectly, by inflaming the skin.

A landmark study showed something more direct.

IL-4 and IL-13 act directly on sensory neurons, and chronic itch depends on neuronal IL-4 receptor alpha and JAK1 signaling. R

In other words, the itch nerve has receptors for the allergic cytokines, and the cytokines speak to the nerve directly. R

This explained two clinical mysteries at once.

It explained why dupilumab (blocking IL-4 and IL-13) relieves itch, and why JAK inhibitors (blocking the JAK1 the nerve uses) relieve even recalcitrant chronic itch that failed other treatments. R

This is the neuro-immune model in its purest form.

The immune cytokine and the sensory nerve are in direct conversation, and you can treat eczema by interrupting that conversation.

NGF, NT-4, And Hyperinnervation

Eczema skin is also physically over-wired.

Atopic dermatitis skin shows increased levels of nerve growth factor (NGF) and the related neurotrophin-4 (NT-4), with upregulated NGF receptors. R

NGF binds TrkA on itch nerves, triggering nerve sprouting and sensitization, so the affected skin literally grows more itch fibers. R

This hyperinnervation is driven partly by a loss of Sema3A, the signal that normally keeps nerves out of the epidermis, and blocking NGF normalizes the nerve density and suppresses the itch in models. R

Mast cells and keratinocytes are the main local sources of this NGF, which ties eczema directly to the mast cell and nerve loop. R

So the itch of eczema is not just a chemical signal.

It is a structurally over-innervated, over-sensitized skin.

The Itch Is Non-Histaminergic

This is the practical key to eczema.

The itch of atopic dermatitis is largely histamine-independent, which is why antihistamines so often fail.

It runs through IL-31, through tryptase acting on proteinase-activated receptor 2 (PAR-2), and through the IL-4/IL-13 nerve signaling above, none of which antihistamines block. R

In eczema, tryptase is elevated and PAR-2 is upregulated on nerve fibers, and itch from mast cell mediators persists even when histamine is blocked. R

For the full breakdown of why this matters and what to do instead, see the dedicated post on the neuroscience of itch.

The short version is that chasing eczema itch with antihistamines is chasing the wrong pathway.

Why Eczema Skin Runs Cold

This is the most overlooked feature of eczema, and one of the most interesting.

Atopic skin is neurovascularly abnormal, with a constitutional tendency toward vasoconstriction.

The classic sign is white dermographism, where stroking the skin produces a white line (from vasoconstriction) instead of the normal red line (from vasodilation). R00917-1/fulltext)

Atopic skin also shows a delayed blanch response to acetylcholine and abnormal vascular reactions to temperature and pressure, all pointing to a hyper-vasoconstrictive microcirculation. R

This is a real, measurable difference confirmed by laser Doppler flow studies, not an artifact of inflammation. R00917-1/fulltext)

Jacob's framing raises a reasonable question here.

If atopic skin runs cold and over-constricted, then strategies that improve microvascular perfusion and nitric oxide signaling, rather than only suppressing inflammation, may be an underexplored angle, though this remains a hypothesis rather than established treatment.

It is a different way to think about a disease everyone treats purely as inflammation.

The Neuropeptide Picture

The neuropeptide story in eczema is truly mixed, and being upfront about that matters.

Counterintuitively, substance P levels are measured as decreased in lesional eczema skin, while vasoactive intestinal peptide (VIP) is elevated. R

This may reflect increased substance P degradation by peptidases and a shift in the neuropeptide balance, rather than substance P being unimportant, since substance P signaling still contributes to itch and flares through its receptors. R

The opioid side is also altered.

POMC-derived beta-endorphin signaling is changed in atopic skin, and the balance of opioid receptors that modulate itch is shifted, which connects eczema itch to the same mu and kappa opioid balance seen in other chronic itch. R

The honest summary is that eczema involves a reorganized, not simply amplified, neuropeptide environment.

That complexity is part of why single-target treatments rarely fully control it.

Stress Flares Eczema

Stress is one of the most consistent eczema triggers, and the mechanism is familiar.

Stress shifts immunity further toward the Th2 pattern that drives eczema, while weakening the skin barrier, a double hit. R

This is covered in detail in the stress and skin post, where chronic stress reliably tilts the immune system toward the allergic, barrier-impaired state.

The itch-scratch cycle then compounds the stress, since the loss of sleep and the constant discomfort are themselves stressors.

Breaking that loop is part of treatment, not separate from it.

The Brain-Skin And Junction Dysfunction Connection

Eczema is a complete brain-skin axis disease, hitting all three arms.

The immune arm (IL-4, IL-13, IL-31) speaks directly to the nerve, the nerve sprouts and sensitizes under NGF, and the vasculature runs abnormally constricted. R

The abnormal microcirculation and barrier leak fit Jacob's Junction Dysfunction lens, where compromised vascular and barrier function underlie chronic disease, and where the neurogenic inflammation and mast cell loop keeps the cycle running.

The practical implication is that eczema is not controllable from the barrier alone.

You have to address the immune skew, the sensitized nerve, and the stress driving both.

What Helps

Effective eczema care works all three arms at once.

1. Repair the barrier relentlessly

Consistent, heavy moisturization with ceramide creams and colloidal oatmeal reduces the irritant and allergen load that reaches the nerves and immune cells.

2. Calm the Th2 immune skew

Vitamin D supports barrier and immune balance, omega-3 fatty acids are anti-inflammatory, and addressing the gut shifts the immune set point, since the gut microbiome strongly shapes the Th1/Th2 balance.

3. Target the nerve and the itch

Because the itch is non-histaminergic, the strategies in the itch post apply: cooling and menthol, mast cell stabilizers like quercetin, and addressing the opioid balance.

4. Reduce stress and the scratch cycle

Nervous-system work directly reduces the Th2 shift and the itch drive, covered in the JD chapter on limbic retraining.

5. Consider the modern targeted treatments

For moderate to severe disease, dupilumab (blocking IL-4/IL-13), nemolizumab (blocking IL-31), and JAK inhibitors (blocking the neuronal JAK1) are highly effective and validate the neuro-immune model. R

Testing

Testing targets the immune, barrier, and trigger drivers.

Blood And Urine Markers

Total IgE and allergen-specific IgE establish the atopic and allergic load, and vitamin D is worth optimizing.

I use the Food Zoomer (Vibrant Wellness) for food sensitivities and the Nutrient Zoomer (Vibrant Wellness) for vitamin D and the fatty acid balance.

Functional Lab Panels

Because the gut shapes the Th2 skew, I use the Gut Zoomer (Vibrant Wellness), and the Immune Zoomer (Vibrant Wellness) for the broader allergic and mast cell picture.

Mechanisms Of Action

Simple:

• Eczema is a broken barrier plus an allergic immune system plus over-sensitive nerves, and the itch comes mostly from the nerves, which is why antihistamines do not fix it.

• The allergic cytokines that cause eczema talk directly to the itch nerves, which is why the newer injectable and JAK drugs stop the itch.

Advanced:

• Direct cytokine-neuron signaling. IL-4 and IL-13 act on neuronal IL-4Rα to sensitize sensory neurons via JAK1; chronic itch depends on this pathway, explaining the efficacy of IL-4/IL-13 blockade and JAK inhibition. R

• NGF-driven hyperinnervation. Elevated NGF and NT-4 with reduced Sema3A increase epidermal nerve density and sensitization; anti-NGF normalizes innervation and reduces itch. R

• Non-histaminergic itch. IL-31, PAR-2/tryptase, and type 2 cytokine signaling drive the itch independent of histamine, accounting for antihistamine failure. R

• Neurovascular dysregulation. Atopic skin shows a constitutional vasoconstrictive tendency (white dermographism, delayed acetylcholine blanch) confirmed by laser Doppler, indicating abnormal microvascular and autonomic control beyond inflammation. R00917-1/fulltext)

Genetics

Atopic dermatitis is strongly heritable.

FLG

FLG encodes filaggrin, the key barrier protein, and loss-of-function variants (such as R501X, rs61816761) are the strongest single genetic risk factor for atopic dermatitis.

IL4, IL13, And IL4RA

These genes encode the central Th2 cytokines and their receptor; the IL-13 R130Q variant (rs20541) and the IL-4 receptor Q576R variant (rs1801275) are atopy-associated, and this axis drives both the allergic inflammation and the direct itch signaling to nerves.

IL31

IL31 encodes the itch cytokine, and variants influence the intensity of the itch in atopic disease.

SPINK5

SPINK5 encodes LEKTI, a protease inhibitor that protects the barrier; the Glu420Lys variant (rs2303067) is associated with atopic dermatitis, and variants increase protease (including tryptase-like) activity and PAR-2 signaling.

More Research

A few additional threads are worth following.

The direct cytokine-to-neuron discovery reframed atopic dermatitis as a neuro-immune disease and is the reason a single class of drugs can address both the inflammation and the itch, which earlier purely immunosuppressive thinking could not predict. R

The neurovascular abnormality of atopic skin is underexplored therapeutically, and whether improving microvascular perfusion adds benefit is an open and interesting question. R00917-1/fulltext)

The mixed neuropeptide picture (decreased substance P, increased VIP, altered opioid signaling) is a reminder that eczema involves a reorganized neuro-immune environment, not a simple excess of one mediator. R

For the itch mechanism see the neuroscience of itch, and for the broader framework, the brain-skin axis pillar.

For biomarker testing I use the Food Zoomer and Gut Zoomer to map the allergic and gut drivers of eczema.

If you have eczema that is not controlled by barrier care and antihistamines, reach out for a consultation.